Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6)....

Full description

Bibliographic Details
Main Authors: Kazufumi Takamatsu, Satoshi Marumo, Motonari Fukui, Atsuko Hata
Format: Article
Language:English
Published: Elsevier 2017-08-01
Series:Journal of Microbiology, Immunology and Infection
Subjects:
Aging
Antiviral drugs
Geriatrics
Gerontology
High-risk patient
Neuraminidase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S1684118217300750
id doaj-a89051da305e4b5a8c4e4b678864432b
record_format Article
spelling doaj-a89051da305e4b5a8c4e4b678864432b2020-11-24T21:08:09ZengElsevierJournal of Microbiology, Immunology and Infection1684-11822017-08-0150454154410.1016/j.jmii.2016.11.006Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying diseaseKazufumi Takamatsu0Satoshi Marumo1Motonari Fukui2Atsuko Hata3Department of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, JapanDepartment of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, JapanDepartment of Respiratory Medicine, Tazuke Kofukai Medical Research Institute Kitano Hospital, JapanDepartment of Pediatrics, Tazuke Kofukai Medical Research Institute Kitano Hospital, JapanWe retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6). Results confirm intravenous peramivir's usefulness.http://www.sciencedirect.com/science/article/pii/S1684118217300750AgingAntiviral drugsGeriatricsGerontologyHigh-risk patientNeuraminidase inhibitor
collection DOAJ
language English
format Article
sources DOAJ
author Kazufumi Takamatsu
Satoshi Marumo
Motonari Fukui
Atsuko Hata
spellingShingle Kazufumi Takamatsu
Satoshi Marumo
Motonari Fukui
Atsuko Hata
Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
Journal of Microbiology, Immunology and Infection
Aging
Antiviral drugs
Geriatrics
Gerontology
High-risk patient
Neuraminidase inhibitor
author_facet Kazufumi Takamatsu
Satoshi Marumo
Motonari Fukui
Atsuko Hata
author_sort Kazufumi Takamatsu
title Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
title_short Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
title_full Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
title_fullStr Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
title_full_unstemmed Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
title_sort safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease
publisher Elsevier
series Journal of Microbiology, Immunology and Infection
issn 1684-1182
publishDate 2017-08-01
description We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4–40.6). Results confirm intravenous peramivir's usefulness.
topic Aging
Antiviral drugs
Geriatrics
Gerontology
High-risk patient
Neuraminidase inhibitor
url http://www.sciencedirect.com/science/article/pii/S1684118217300750
work_keys_str_mv AT kazufumitakamatsu safetyandefficacyofantiinfluenzadrugsintravenousperamiviragainstinfluenzavirusinfectioninelderlypatientswithunderlyingdisease
AT satoshimarumo safetyandefficacyofantiinfluenzadrugsintravenousperamiviragainstinfluenzavirusinfectioninelderlypatientswithunderlyingdisease
AT motonarifukui safetyandefficacyofantiinfluenzadrugsintravenousperamiviragainstinfluenzavirusinfectioninelderlypatientswithunderlyingdisease
AT atsukohata safetyandefficacyofantiinfluenzadrugsintravenousperamiviragainstinfluenzavirusinfectioninelderlypatientswithunderlyingdisease
_version_ 1716760685803732992

Similar Items